Requires Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.
Summary
Assembly Bill 4748 would amend New Jersey’s Medicaid statute to require coverage, when federal matching funds are available, for medically necessary ovulation-enhancing drugs and related medical services for Medicaid beneficiaries ages 21 through 44 who are experiencing infertility. The bill defines infertility by reference to the inability to achieve a clinical pregnancy after 12 months of regular unprotected intercourse for people ages 21 through 34, or after 6 months for people ages 35 through 44.
The covered services are limited to office visits, hysterosalpingograms, pelvic ultrasounds, and blood testing, and the drug and service coverage is capped at three treatment cycles per beneficiary’s lifetime. The bill also directs the Commissioner of Human Services to seek any necessary state plan amendments or waivers and to adopt implementing regulations, and it would take effect on the first day of the fourth month after enactment.
Impact
The bill would expand the scope of New Jersey Medicaid benefits by adding an infertility-related prescription drug and diagnostic service benefit for eligible adults, contingent on federal financial participation. It would amend P.L.1968, c.413 (C.30:4D-6), the state’s Medicaid enabling statute, and would require the Department of Human Services to pursue federal approvals and promulgate rules to implement the new coverage. The practical effect would be to make certain fertility-related treatment more accessible to Medicaid beneficiaries, while limiting the benefit to a narrow set of services and a lifetime cap of three cycles.
Sentiment
The bill text and sponsor statement present the measure as a targeted expansion of reproductive health coverage, and the statement explicitly notes that it mirrors an existing infertility benefit in New York. Because there are no committee transcripts or recorded votes provided, there is no documented floor or committee debate to indicate broader legislative sentiment. Based on the bill’s structure, the overall posture appears supportive of expanding Medicaid coverage for infertility treatment, but only within defined clinical and fiscal limits.
Contention
The main points of potential contention are likely to be cost, federal approval, and the scope of the benefit. Supporters would likely emphasize access to infertility treatment for low-income adults, while critics may question whether Medicaid should cover fertility-related drugs and diagnostics at all, especially given the lifetime cap and the requirement that federal financial participation be available. The age range, the definition of infertility, and the restriction to specific tests and three cycles per lifetime are all likely designed to narrow the benefit and may reflect an effort to address budgetary or policy concerns.
Same As
Requires Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.
Carry Over
Requires Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.